Therapy Areas: Devices
ImmunSYS Adds Maroon, Link, and Schwartz to Its Board of Directors
27 June 2019 - - US-based biotechnology company ImmunSYS, Inc has added Joseph C. Maroon, M.D., Charles J. Link, M.D., Jeffery L. Cleland, Ph.D., and Norman D. Schwartz to its board of directors, the company said.
Maroon is a clinical professor and vice chairman of the Department of Neurological Surgery and Heindl Scholar in Neuroscience at the University of Pittsburgh Medical Center. He is regarded as a premiere specialist in the surgical treatment of injuries and diseases of the brain and spine, specialising in minimally invasive procedures.
Maroon has been the team neurosurgeon for the Pittsburgh Steelers since 1981 and is Medical director of the World Wrestling Entertainment.
Link is the co-founder, chairman and chief executive officer of NewLink Genetics, a clinical stage company focused on the development of new immuno-oncology treatments. Link co-founded NewLink Genetics in 1999 with the idea of leveraging the body's immune system to fight cancer.
Link practiced oncology for 18 years, most recently caring for patients part-time at Medical Oncology and Hematology Associates of Iowa from 1995 to 2013. He also served as director of the Human Gene Therapy Research Institute, which is part of the John Stoddard Cancer Center at Iowa Methodist Medical Center.
Link was appointed by United States Senator John Glenn of Ohio to the United States Air Force Academy where he studied chemistry.
Prior to graduating, he was accepted to a special programme at Stanford University School of Medicine in Stanford, California, where he received his bachelor's degree in chemistry and his medical degree.
He interned at the University of California, San Francisco, and completed his residency and fellowship training in medical oncology at the National Cancer Institute in Bethesda, Maryland, where he also served as an attending physician.
Cleland is the Executive chair and Co-Founder of Orpheris, a clinical stage neuroscience company. He has 25 years of industry experience in research and development, including more than a decade at Genentech, Inc.
His experience in startups includes major roles in obtaining more than USD 450m in capital at stages from series A through D and exit via IPO including over USD 300m in capital raised as CEO.
As the founding CEO of Versartis, he led one of top biotech IPOs of all time.
He has held executive management positions at BaroFold, Novacea and Targesome, and has managed directly all aspects of pharmaceutical development and late-stage research. While at Genentech, Dr. Cleland served in product development and manufacturing roles.
He held leadership roles in the successful approval of two drugs, Herceptin and Nutropin Depot, as well as in early work on Lucentis, Avastin, and Omnitarg. He holds a BS in Chemical Engineering from the University of California, Davis and a PhD in Chemical Engineering from the Massachusetts Institute of Technology. Dr. Cleland has authored more than 100 articles and four books and holds several issued patents.
Schwartz is the chairman, president and CEO of Bio-Rad Laboratories, which provides innovative products and solutions for the life science research and clinical diagnostic markets.
He assumed the chief executive officer position in January 2003 after successfully running the Life Science and Diagnostics Groups of Bio-Rad.
Since assuming the CEO role, the company listed on the NYSE and gained investment grade status for its debt securities.
Schwartz also has extensive international experience, including managing director of the Microscience division in the UK and president of Nippon Bio-Rad in Japan.
He began his career with Bio-Rad in 1974, holding various operations, accounting and finance positions. Schwartz received a Business Administration degree from California State University, San Francisco.
ImmunSYS is a clinical stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products to improve the lives of patients with late-stage metastatic prostate cancer and other adenocarcinomas.
The company's platform technology, YourVaccx utilises a novel combination of the proprietary Antigenerator energy delivery device system, a proprietary branded formulation of immunotherapeutic drugs, and a proprietary procedure developed by the focal prostate cancer pioneer and inventor of the male lumpectomy, Gary Onik, M.D.
This new immunotherapy therapy is designed to empower the immune system to recognize and selectively attack cancer cells. The company is initially developing this new cancer therapy for the treatment of late-stage metastatic prostate cancer, with a pipeline of additional development programmes for other cancers.
Login
Username:

Password: